NTLA Relative Valuation
NTLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NTLA is overvalued; if below, it's undervalued.
Historical Valuation
Intellia Therapeutics Inc (NTLA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -11.19. The fair price of Intellia Therapeutics Inc (NTLA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：9.46
Fair
-2.45
PE
1Y
3Y
5Y
Trailing
Forward
-1.00
EV/EBITDA
Intellia Therapeutics Inc. (NTLA) has a current EV/EBITDA of -1.00. The 5-year average EV/EBITDA is -8.50. The thresholds are as follows: Strongly Undervalued below -26.52, Undervalued between -26.52 and -17.51, Fairly Valued between 0.52 and -17.51, Overvalued between 0.52 and 9.53, and Strongly Overvalued above 9.53. The current Forward EV/EBITDA of -1.00 falls within the Historic Trend Line -Fairly Valued range.
-1.02
EV/EBIT
Intellia Therapeutics Inc. (NTLA) has a current EV/EBIT of -1.02. The 5-year average EV/EBIT is -9.09. The thresholds are as follows: Strongly Undervalued below -30.79, Undervalued between -30.79 and -19.94, Fairly Valued between 1.75 and -19.94, Overvalued between 1.75 and 12.60, and Strongly Overvalued above 12.60. The current Forward EV/EBIT of -1.02 falls within the Historic Trend Line -Fairly Valued range.
24.65
PS
Intellia Therapeutics Inc. (NTLA) has a current PS of 24.65. The 5-year average PS is 91.08. The thresholds are as follows: Strongly Undervalued below -62.35, Undervalued between -62.35 and 14.37, Fairly Valued between 167.80 and 14.37, Overvalued between 167.80 and 244.51, and Strongly Overvalued above 244.51. The current Forward PS of 24.65 falls within the Historic Trend Line -Fairly Valued range.
-2.94
P/OCF
Intellia Therapeutics Inc. (NTLA) has a current P/OCF of -2.94. The 5-year average P/OCF is -12.09. The thresholds are as follows: Strongly Undervalued below -33.36, Undervalued between -33.36 and -22.73, Fairly Valued between -1.45 and -22.73, Overvalued between -1.45 and 9.19, and Strongly Overvalued above 9.19. The current Forward P/OCF of -2.94 falls within the Historic Trend Line -Fairly Valued range.
-2.87
P/FCF
Intellia Therapeutics Inc. (NTLA) has a current P/FCF of -2.87. The 5-year average P/FCF is -13.14. The thresholds are as follows: Strongly Undervalued below -39.30, Undervalued between -39.30 and -26.22, Fairly Valued between -0.07 and -26.22, Overvalued between -0.07 and 13.01, and Strongly Overvalued above 13.01. The current Forward P/FCF of -2.87 falls within the Historic Trend Line -Fairly Valued range.
Intellia Therapeutics Inc (NTLA) has a current Price-to-Book (P/B) ratio of 1.40. Compared to its 3-year average P/B ratio of 2.23 , the current P/B ratio is approximately -37.20% higher. Relative to its 5-year average P/B ratio of 4.82, the current P/B ratio is about -70.94% higher. Intellia Therapeutics Inc (NTLA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -21.30%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.21% , the current FCF yield is about -100.00% lower.
1.51
P/B
Median3y
2.23
Median5y
4.82
-39.32
FCF Yield
Median3y
-21.30
Median5y
-14.21
Competitors Valuation Multiple
The average P/S ratio for NTLA's competitors is 0.00, providing a benchmark for relative valuation. Intellia Therapeutics Inc Corp (NTLA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 51.27%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NTLA decreased by 16.47% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 9.11M to 13.78M.
The secondary factor is the P/E Change, contributed -17.10%to the performance.
Overall, the performance of NTLA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Intellia Therapeutics Inc (NTLA) currently overvalued or undervalued?
What is Intellia Therapeutics Inc (NTLA) fair value?
How does NTLA's valuation metrics compare to the industry average?
What is the current P/B ratio for Intellia Therapeutics Inc (NTLA) as of Dec 05 2025?
What is the current FCF Yield for Intellia Therapeutics Inc (NTLA) as of Dec 05 2025?
What is the current Forward P/E ratio for Intellia Therapeutics Inc (NTLA) as of Dec 05 2025?